Keros halts parts of Phase 2 PAH trial due to safety, stock tanks 70%
Keros Therapeutics said Thursday morning it has voluntarily halted two of three dosing arms of its experimental drug in a Phase 2 trial due to a safety concern. The Boston-area biotech said there was...
View ArticlePfizer shares positive Phase 3 results in breast cancer subset
Pfizer touts Ibrance’s status as a standard of care in HR-positive, HER2-negative metastatic breast cancer. Now the company wants to expand to HER2-positive patients. On Thursday, the drugmaker...
View ArticleIsomorphic Labs CEO Demis Hassabis bets on biotech's AI future
LONDON — Demis Hassabis has no interest in a laboratory. The Nobel Prize-winning artificial intelligence pioneer is betting big on AI’s future in drug discovery. But he’s also grown exasperated at...
View ArticleEli Lilly and Ro’s unlikely relationship
Over the summer, we speculated that the cold war between drugmakers Eli Lilly and Novo Nordisk and the many businesses profiting from copycat versions of their obesity medications would come ...
View ArticleDaiichi's $150M build in China; BioMarin reveals €60M Irish expansion
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Daiichi Sankyo is investing RMB 1.1 billion ...
View ArticleElevation to pay up to $368M in ADC deal; Bavarian Nordic closes San Diego site
Plus, news about Essential Pharma, ADC Therapeutics, Caliway Biopharmaceuticals, AnaptysBio, Andera Partners and NewAmsterdam Pharma: Elevation’s ADC deal: The biotech will pay up to $368 million in...
View ArticlePadlock shareholders sue Bristol Myers over milestone dispute after 2016...
Former shareholders in autoimmune biotech acquired by Bristol Myers Squibb are suing the large pharma for what they claim are missed milestone payments and maneuvers to discredit the biotech’s work. BMS
View Article'Unsupported' drug price increases add to US costs, ICER claims
The Institute for Clinical and Economic Review on Thursday released a new report arguing that US healthcare costs rose by more than $800 million from price increases on just five drugs' net prices,...
View Article'Serious liver injury' cases on Ocaliva lead FDA to call for monitoring
The FDA said it continues to monitor the safety of Intercept Pharmaceuticals and Alfasigma’s rare liver disease drug Ocaliva after seeing evidence of “serious liver injury” in a post-approval clinical...
View ArticleFDA adcomm reviews safety signals from pediatric RSV trials
Advisors to the FDA had difficulty dissecting a small but concerning set of safety data from Moderna’s pediatric RSV vaccine data, largely concluding that other trials should continue to better inform...
View ArticleEditas to cut 65% of workforce, officially stops work on ex vivo sickle cell...
Editas Medicine will eliminate about 180 roles after failing to find a commercial partner for its experimental sickle cell therapy, and will halt development of the treatment, the company said...
View ArticleGilead names Dietmar Berger CMO as it eyes R&D reset
Gilead Sciences has tapped Sanofi’s Dietmar Berger as its next chief medical officer in a bid to shake up its strategy at the tail end of a mostly negative year. The new CMO will join ...
View ArticleiTeos drops adenosine A2A antagonist inupadenant to double down on TIGIT
iTeos Therapeutics will set aside inupadenant following lackluster mid-stage data in non-small cell lung cancer. The company will focus on its TIGIT therapies instead, with its recent positive data...
View ArticleXaira hires former Roche exec as CMO; 'Tis the season for retirements at...
The billion-dollar AI-focused startup Xaira Therapeutics deepened its C-suite this week, hiring former Roche executive Paulo Fontoura as its chief medical officer and internally promoting co-founder...
View ArticleAbbVie makes another small I&I acquisition, buying Nimble for $200M
In an attempt to continue its I&I dominance beyond Humira, Skyrizi and Rinvoq, AbbVie is buying up another small autoimmune startup. The Chicago-area pharma giant is dishing out $200 million...
View ArticleEisai subsidiary nabs Japan rights for schizophrenia drug; Novavax's $50M...
Plus, news about Candel, Inovio and RemeGene: Eisai licenses Newron Pharmaceuticals’ evenamide: Eisai’s subsidiary EA Pharma will pay up to €117 million ($123 million) in upfront and milestone fees for...
View ArticleRepare plans for Phase 3 endometrial cancer study, sidelining ovarian cancer
Repare Therapeutics announced that a combination of two targeted drugs resulted in confirmed responses of 19% and 17% in endometrial cancer and ovarian cancer, respectively, and now plans to take the...
View ArticleSABCS Roundup: BeiGene and Pfizer CDK4 inhibitors, ALX’s CD47
This year’s San Antonio Breast Cancer Conference yielded major clinical updates on some of the hottest areas of oncology, from VEGF bispecifics that hope to challenge Merck’s Keytruda on efficacy to ...
View ArticleBeiGene licenses MAT2A cancer drug, matches with Ideaya’s combo plans
BeiGene said it will take on an early-stage drug for solid tumors with MTAP deletion for $150 million upfront and "time-based payments," in a move that would put it in a contest with Ideaya’s combo ...
View Article